Grifols’ Canadian License Restricted After Plasma Deaths

Spanish drugmaker Grifols SA is facing restrictions on its Canadian license to collect blood products following the deaths of two patients who made plasma donations in the country.

Health Canada, which oversees health policy, cited “recurring, systemic deficiencies across several sites” as the reason for placing terms and conditions on Grifols’ blood establishment license. The regulator also issued non-compliance ratings to Grifols’ Canadian head office and collection sites in Calgary and Regina, Saskatchewan.